Portfolio
3
companies
Lightcast Discovery
Lightcast Discovery builds a novel single-cell functional analysis platform for life science research.
ONI
ONI develops desktop super-resolution microscopes for cellular and molecular research.
Syndex Bio
Syndex Bio advances next-generation molecular diagnostics with its proprietary methyl-copying PCR platform.
Keith Crandell
Co-founder and Managing Director
ARCH Venture Partners led the oversubscribed round alongside participation from +ND Capital, OMX Ventures, and Meltwind.
"Syndex Bio’s mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring."
M Ventures led the Series B round to support the company ahead of its commercial launch.
"The power of single-cell analysis to uncover the complexities of biology has become increasingly evident, but much of the work still focuses on the transcriptome as the primary readout."
The Oxford biotech spinout secured $75m to expand international operations and scale its microscopy platform.
"ONI’s technology democratises cutting-edge science, enabling researchers to develop new angles to explore and understand the complexity of biological systems at super-resolution,"
